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Psoriasis in the US Medicare Population: Prevalence,
Treatment, and Factors Associated with Biologic Use
Junko Takeshita1,2, Joel M. Gelfand1,2, Penxiang Li3,4, Lionel Pinto5, Xinyan Yu3,4, Preethi Rao4,6,
Hema N. Viswanathan5 and Jalpa A. Doshi3,4
Psoriasis is a common chronic inﬂammatory disorder, primarily of the skin. Despite an aging population,
knowledge of the epidemiology of psoriasis and its treatments among the elderly is limited. We examined the
prevalence of psoriasis and its treatments, with a focus on biologics and identiﬁcation of factors associated with
biologic use, using a nationally representative sample of Medicare beneﬁciaries in 2011. On the basis of several
psoriasis identiﬁcation algorithms, the claims-based prevalence for psoriasis in the United States ranged from
0.51 to 1.23%. Treatments used for moderate-to-severe psoriasis (phototherapy, oral systemic, or biologic
therapies) were received by 27.3% of the total psoriasis sample, of whom 37.2% used biologics. Patients without a
Medicare Part D low-income subsidy (LIS) had 70% lower odds of having received biologics than those with LIS
(odds ratio 0.30; 95% conﬁdence interval, 0.19–0.46). Similarly, the odds of having received biologics were 69%
lower among black patients compared with white patients (0.31; 0.16–0.60). This analysis identiﬁed potential
ﬁnancial and racial barriers to receipt of biologic therapies and underscores the need for additional studies to
further deﬁne the epidemiology and treatment of psoriasis among the elderly.
Journal of Investigative Dermatology (2015) 135, 2955–2963; doi:10.1038/jid.2015.296; published online 20 August 2015
INTRODUCTION
Psoriasis is a common, chronic, multisystem, inﬂammatory
disease of the skin and sometimes joints. Approximately 7.5
million Americans (National Psoriasis Foundation) are affected
by psoriasis, resulting in a prevalence of 2 to 4% in the United
States according to population-based estimates (Gelfand et al.,
2005b; Kurd and Gelfand, 2009; Rachakonda et al., 2014).
Psoriasis is associated with signiﬁcant economic (Feldman
et al., 2014), psychosocial (Kimball et al., 2005), and physical
(Yeung et al., 2013) health burdens that are proportional to
disease severity. An increasing body of epidemiologic literature
provides evidence that psoriasis, particularly more severe
disease, is independently associated with increased risks of
major adverse cardiovascular events (Gelfand et al., 2006a,
2009; Mehta et al., 2010), diabetes (Azfar et al., 2012), renal
disease (Wan et al., 2013), and other emerging comorbid
diseases (Yeung et al., 2013).
Treatment options for psoriasis include topical therapies,
phototherapy, and systemic medications. Moderate-to-severe
psoriasis, which affects nearly 25% of patients with the
disease (National Psoriasis Foundation), is an indication for
treatment with phototherapy, oral systemics (i.e., metho-
trexate, cyclosporine, or acitretin), or biologics, whereas mild
disease is generally treated with topical therapies alone.
Psoriatic arthritis, which affects 6 to 17% of patients with
psoriasis according to population-based studies (Shbeeb et al.,
2000; Gelfand et al., 2005a; Ibrahim et al., 2009; Wilson
et al., 2009; Ogdie et al., 2013; Lofvendahl et al., 2014), is an
indication for treatment with oral systemic or biologic
therapies. In the last decade, several new therapies for
moderate-to-severe psoriasis have been approved, primarily
driven by the development of targeted biologics including
tumor necrosis factor, IL-12/-23, and IL-17 inhibitors. Yet most
psoriasis patients remain inadequately treated and dissatisﬁed
with their therapies (Horn et al., 2007; Armstrong et al., 2013).
Furthermore, access to biologics remains a challenge for
many patients because of limited insurance coverage,
prohibitive costs, and other factors (Polinski et al., 2009;
Kamangar et al., 2013; Romanelli et al., 2015).
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Despite marked progress in the understanding of the
epidemiology, pathophysiology, and treatment of psoriasis
during recent years, major knowledge gaps still exist,
particularly regarding the prevalence of and treatment
patterns for psoriasis among the growing elderly population,
which, in the United States, is estimated to reach 79.7 million
by 2040 (United States Department of Health and Human
Services Administration on Aging, 2012). As over 90%
(Centers for Medicare and Medicaid Services, 2011) of the
elderly (65 years and older) population in the United States
receive medical coverage through the Medicare system, the
aim of our study was to investigate the prevalence of psoriasis
among Medicare beneﬁciaries who are actively receiving
medical care, examine their clinical characteristics, and
determine the prevalence of psoriasis therapies, with a focus
on biologic use and factors associated with receiving biologic
treatment.
RESULTS
Claims based psoriasis prevalence
Claims based psoriasis prevalence was determined for 799,607
beneﬁciaries in the 2011 5% Medicare sample using eight
different algorithms (Table 1). Using the International Classiﬁ-
cation of Diseases, Ninth Revision, Clinical Modiﬁcation
(ICD-9-CM) 696.1 code to identify psoriasis, claims based
prevalence ranged from 1.13% (95% conﬁdence interval (CI):
1.10–1.15) using an algorithm identifying at least one inpatient
or outpatient claim for psoriasis to 0.51% (95% CI: 0.50–0.53)
using an algorithm identifying at least one inpatient or
outpatient claim for psoriasis made by a dermatologist. We
also explored a broader method of identifying psoriasis using
claims for either psoriasis or psoriatic arthritis (ICD-9-CM
696.0). Claims based psoriasis prevalence using this method
ranged from 1.23% (95% CI: 1.20–1.25) to 0.60% (95% CI:
0.58–0.61). For our main analyses, we identiﬁed psoriasis by
the presence of at least two inpatient or outpatient claims for
psoriasis, which resulted in a prevalence of 0.58% (95% CI:
0.56–0.60).
Psoriasis patient characteristics
Psoriasis patient and Medicare plan characteristics are
summarized in Table 2. The mean age of psoriasis patients
was 68.6 years (standard deviation (SD), 13.4); 43.2% were
male, and 88.8% were white. Regional distribution was as
follows: 24.0% in the Northeast, 23.0% in the Midwest, 36.2%
in the South, and 16.6% in the West. County-level mean per
capita income was $40,115 (SD, $11,817). Average number of
dermatologists per 100,000 county residents was 3.6 (SD, 3.6).
The majority of beneﬁciaries qualiﬁed for Medicare based
on age alone (63.6%). Most beneﬁciaries were not receiving
a Medicare Part D low-income subsidy (LIS) (58.4%). Only
19.0% of the beneﬁciaries were receiving Part D plans with
enhanced alternative coverage. The most commonly coded
comorbidities among beneﬁciaries with psoriasis were cardio-
metabolic disorders: 67.6% with hypertension, 59.9% with
dyslipidemia, and 32.4% with diabetes; 23.5% had athero-
sclerotic outcomes. In contrast, the prevalence of obesity was
relatively low at 9.3%. The prevalence of psoriatic arthritis was
9.4%, which is similar to population-based estimates of
psoriatic arthritis among patients with psoriasis (Ogdie et al.,
2013). Other comorbid diseases of interest include
inﬂammatory bowel disease (1.2%), liver disease (5.1%),
depression (17.1%), and renal disease (9.8%). As indicators of
overall comorbidity, the average number of non-psoriasis
medications received was 4.7 (SD, 3.4), and the mean
prescription drug hierarchical condition category (RxHCC)
score was 1.0 (SD, 0.6).
Psoriasis therapy prevalence
The prevalence of therapies received by Medicare beneﬁciaries
with psoriasis is summarized in Table 3. Most patients had at
least one claim for psoriasis therapy (83.5%), and 16.5%
received no therapy. Topical therapies were used by 76.6%
(N=3,551), the majority of whom received topical cortico-
steroids (97.9%). Phototherapy was used by 7% (N=324).
Oral systemic medications were used by 14.3% (N=664), the
majority of whom received methotrexate (85.7%). Biologics
Table 1. Claims based psoriasis prevalence1
Psoriasis identiﬁcation algorithm N % (95% Conﬁdence interval)
ICD-9-CM 696.1 (psoriasis)
At least 1 inpatient or outpatient claim 9,017 1.13 (1.10–1.15)
At least 1 inpatient or 2 outpatient claims 4,925 0.62 (0.60–0.63)
At least 2 inpatient or outpatient claims 4,638 0.58 (0.56–0.60)
At least 1 inpatient or outpatient claim by dermatologist 4,096 0.51 (0.50–0.53)
ICD-9-CM 696.1 (psoriasis) or 696.0 (psoriatic arthritis)
At least 1 inpatient or outpatient claim 9,827 1.23 (1.20–1.25)
At least 1 inpatient or 2 outpatient claims 5,695 0.71 (0.69–0.73)
At least 2 inpatient or outpatient claims 5,398 0.68 (0.66–0.69)
At least 1 inpatient or outpatient claim by dermatologist or rheumatologist 4,772 0.60 (0.58–0.61)
Abbreviation: ICD-9-CM, International Classiﬁcation of Diseases, Ninth Revision, Clinical Modiﬁcation.
1Of 799,607 beneﬁciaries in the 2011 5% Medicare sample.
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Table 2. Psoriasis patient characteristics1
Characteristic
Number (%)
N=4,638
Age, mean (SD) 68.6 (13.4)
Age (category)
o65 1,237 (26.7)
65–69 934 (20.1)
70–74 912 (19.7)
75–79 681 (14.7)
≥80 874 (18.8)
Sex, male 2,002 (43.2)
Race
White 4,118 (88.8)
Black 236 (5.1)
Latino 104 (2.2)
Other/unknown 180 (3.9)
Census region
Northeast 1,113 (24.0)
Midwest 1,069 (23.0)
South 1,678 (36.2)
West 770 (16.6)
County-level characteristics
Income, per capita/10,000, mean (SD) 4.0 (1.2)
County poverty rate,2 mean (SD) 15.5 (5.3)
Residence in urban county 3,611 (78.2)
Residence in county with low educational level3 520 (11.3)
Number of primary care providers4 per 10,000 residents,
mean (SD)
6.3 (3.0)
Number of dermatologists per 100,000 residents,
mean (SD)
3.6 (3.6)
Medicare eligibility
Aged 2,952 (63.6)
Disabled 1,237 (26.7)
Aged plus disabled 449 (9.7)
LIS status
Full 1,838 (39.6)
Partial 47 (1.0)
None 2,709 (58.4)
Mixed 44 (0.9)
Comorbidities
AIDS/HIV 18 (0.39)
Autoimmune disease
Ankylosing spondylitis 74 (1.6)
Inﬂammatory bowel disease 55 (1.2)
Rheumatoid arthritis 290 (6.3)
Rheumatologic disease 382 (8.2)
Cardiometabolic disease
Cerebrovascular disease 497 (10.7)
Congestive heart failure 515 (11.1)
Table 2. (Continued)
Characteristic
Number (%)
N=4,638
Diabetes 1,503 (32.4)
Dyslipidemia 2,776 (59.9)
Hypertension 3,137 (67.6)
Myocardial infarction 159 (3.4)
Obesity 431 (9.3)
Peripheral vascular disease 636 (13.7)
Atherosclerotic outcomes (aggregate of
cerebrovascular disease, myocardial infarction,
and peripheral vascular disease)
1,091 (23.5)
Hemiplegia or paraplegia 49 (1.1)
Liver disease
Mild liver disease 208 (4.5)
Moderate-to-severe liver disease 27 (0.58)
Malignant disease
Cancer 518 (11.2)
Metastatic solid tumor 37 (0.80)
Neuropsychiatric disease
Dementia 134 (2.9)
Depression 794 (17.1)
Peptic ulcer disease 59 (1.3)
Psoriatic arthritis 436 (9.4)
Pulmonary disease, chronic 1,108 (23.9)
Renal disease 455 (9.8)
Non-psoriasis medications
Number of 30-day supply equivalent prescriptions for
non-psoriasis medications, mean (SD)
4.7 (3.4)
Type of Medicare Part D plan 5
Basic 3,491 (75.3)
Enhanced 879 (19.0)
Unknown 268 (5.8)
RxHCC score, mean (SD) 1.0 (0.6)
Abbreviations: GED, general educational development; ICD-9-CM, Inter-
national Classiﬁcation of Diseases, Ninth Revision, Clinical Modiﬁcation;
LIS, low-income subsidy; RxHCC, prescription drug hierarchical condition
category risk score; SD, standard deviation.
1Psoriasis is deﬁned by at least two inpatient or outpatient claims for
psoriasis (ICD-9-CM 696.1).
2County poverty rate is deﬁned as the percentage of persons in the county
living in poverty.
3County with low educational level is deﬁned by at least 25% of residents
not having a high school diploma or GED in the patient’s county of
residence.
4Primary care providers included medical providers practicing in the ﬁelds
of general family medicine, general practice, and general internal
medicine.
5Basic plans include deﬁned standard beneﬁt, actuarially equivalent
standard, and basic alternative type of Part D plans. Enhanced plans
include enhanced alternative type of Part D plans.
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were received by 10.2% (N=471), among whom speciﬁc
biologic use was distributed as follows: 44.4% etanercept,
34.2% adalimumab, 22.7% inﬂiximab, and 7.9% ustekinumab.
Among biologic users, 31.0% used a physician-administered
drug (i.e., alefacept, inﬂiximab, or ustekinumab), and 78.6%
used a self-administered medication (i.e., adalimumab or
etanercept). Of those who used biologics, 61.8% of patients
received biologics only (with or without topical therapies), and
the remaining 38.2% also received oral systemics and/or
phototherapy during the year.
In the absence of direct measures of psoriasis severity in
claims data, we used psoriasis treatment as a surrogate to
deﬁne mild versus moderate-to-severe disease. Patients who
received either no therapy or topical therapies only were
considered to have mild psoriasis and those who received
phototherapy, oral systemics, or biologics were considered to
have moderate-to-severe psoriasis. Using this method, 70.9%
of patients had mild disease, and 27.3% had moderate-
to-severe disease (Table 4). Of patients identiﬁed to have
moderate-to-severe psoriasis, phototherapy was used by
25.6%, oral systemics by 52.4%, and biologics by 37.2%.
Factors associated with biologic use
In multivariate analyses, we identiﬁed factors associated with
biologic use among patients receiving therapies consistent with
moderate-to-severe psoriasis. Factors associated with a lower
likelihood of receiving biologics were as follows: higher
primary care provider density (odds ratio (OR) 0.92; 95% CI:
0.86–0.98), absence of Part D LIS (OR 0.30; 95% CI: 0.19–
0.46), black race (OR 0.31; 95% CI: 0.16–0.60), and comorbid
cancer (OR 0.47; 95% CI: 0.31–0.72) and dementia (OR 0.26;
95% CI: 0.07–0.97) (Table 5). Factors associated with a greater
likelihood of biologic use included the following: higher
dermatology provider density (OR 1.08; 95% CI: 1.01–1.16),
residence in an urban county (OR 1.54; 95% CI: 1.13–2.11),
and comorbid ankylosing spondylitis (OR 2.26; 95% CI;
1.13–4.53), inﬂammatory bowel disease (OR 8.11; 95% CI:
1.91–34.5), psoriatic arthritis (OR 3.79; 95% CI: 2.74–5.24),
and renal disease (OR: 2.03, 95% CI: 1.24–3.35).
DISCUSSION
In this nationally representative sample of Medicare fee-
for-service beneﬁciaries with Part D drug coverage, we
Table 3. Psoriasis therapy prevalence1
Therapy
Number (%)2
N=4,638
Topicals3 3,551 (76.6)
Corticosteroids 3,477 (75.0)
Class I 1,846 (39.8)
Non-class I 2,718 (58.6)
Calcineurin inhibitors 121 (2.6)
Vitamin D analogs 643 (13.9)
Retinoids 21 (0.45)
Salicylic acid 12 (0.17)
Phototherapy 324 (7.0)
Psoralen plus UVA 34 (0.73)
Excimer laser 126 (2.7)
Oral systemics 664 (14.3)
Methotrexate 569 (12.3)
Cyclosporine 22 (0.47)
Acitretin 90 (1.9)
Biologics4 471 (10.2)
Part B (physician-administered) 146 (3.1)
Inﬂiximab 107 (2.3)
Ustekinumab 37 (0.80)
Part D (self-injectables) 370 (8.0)
Adalimumab 161 (3.5)
Etanercept 209 (4.5)
Abbreviations: CMS, Centers for Medicare and Medicaid Services;
ICD-9-CM, International Classiﬁcation of Diseases, Ninth Revision,
Clinical Modiﬁcation.
1Psoriasis is deﬁned by at least two inpatient or outpatient claims for
psoriasis (ICD-9-CM 696.1).
2Percentages do not equal 100 because patients may have received more
than one therapy.
3Coal tar/anthralin use was examined but not reported separately per CMS
data use agreement because of cell size of 10 or less.
4Alefacept was examined but not reported separately per CMS data use
agreement because of cell size of 10 or less.
Table 4. Psoriasis severity
Severity deﬁned by therapy
Number (%)1
N= 4,638
Mild (n= 3,289; 70.9%)
No therapy 763 (23.2)2
Topicals only 2,526 (76.8)2
Moderate-to-severe3 (n= 1,267; 27.3%)
Phototherapy 324 (25.6)4
Oral systemics 664 (52.4)4
Methotrexate 569 (44.9)4
Cyclosporine 22 (1.7)4
Acitretin 90 (7.1)4
Biologics 471 (37.2)4
Adalimumab 161 (12.7)4
Etanercept 209 (44.4)4
Inﬂiximab 107 (16.5)4
Ustekinumab 37 (2.9)4
Unknown (n= 82; 1.8%)
Abbreviation: CMS, Centers for Medicare and Medicaid Services.
1Percentages do not equal 100 because patients may have received more
than one therapy.
2Percentages are calculated among those with mild psoriasis.
3Alefacept was included as a biologic therapy to identify moderate-to-
severe psoriasis but not reported separately per CMS data use agreement
because of cell size of 10 or less.
4Percentages are calculated among those with moderate-to-severe
psoriasis.
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determined claims based psoriasis prevalence and examined
the clinical characteristics, treatment prevalence, and factors
associated with biologic use for patients with psoriasis.
Claims based psoriasis prevalence ranged from 0.51 to
1.23%, depending on the identiﬁcation algorithm used. These
prevalence estimates were lower than what has been reported
in population-based studies (Gelfand et al., 2005b; Kurd and
Gelfand, 2009; Rachakonda et al., 2014), perhaps because
patients with milder disease do not seek medical care for their
skin disease and/or because of the presence of other barriers
to receiving psoriasis care. The distribution of comorbid
diseases among psoriasis patients was as expected, with the
most common comorbidities being related to cardiometabolic
disease. With the exception of obesity, the prevalence of
cardiometabolic comorbidities was generally greater than
what has previously been reported for the general population
(Neimann et al., 2006; Yeung et al., 2013), and is likely, in
part, attributable to our focus on an elderly population that is
more likely to suffer from comorbid conditions (Sundquist
et al., 2001). Prevalence of cardiometabolic diseases and
Table 5. Factors associated with biologic use among patients receiving therapy indicated for moderate to severe
psoriasis1
Characteristics Status
Unadjusted odds
ratio (95%
conﬁdence interval)
Adjusted odds
ratio2 (95%
conﬁdence interval)
Adjusted rate, %
(95% conﬁdence
interval)
Factors associated with higher odds of biologic use
Dermatology provider density 1.01 (0.98–1.04) 1.08 (1.01–1.16)
3.4 per 100,000
(sample mean)
37.4 (35.3–39.5)
4.4 per 100,000
(one unit increase)
38.9 (36.4–41.3)
Residence in Urban County No Reference 31.5 (26.9–36.1)
Yes 1.22 (0.94–1.60) 1.54 (1.13–2.11) 39.2 (36.8–41.7)
Ankylosing spondylitis No Reference 37.3 (35.2–39.4)
Yes 2.52 (1.24–5.09) 2.26 (1.13–4.53) 52.5 (39.2–65.9)
Inﬂammatory bowel disease No Reference 37.3 (35.2–39.4)
Yes 7.46 (2.29–24.3) 8.11 (1.91–34.5) 75.6 (53.5–97.7)
Psoriatic arthritis No Reference 30.7 (28.2–33.2)
Yes 3.71 (2.85–4.83) 3.79 (2.74–5.24) 57.3 (51.8–62.8)
Renal disease No Reference 36.1 (33.8–38.4)
Yes 1.45 (1.00–2.11) 2.03 (1.24–3.35) 49.5 (40.6–58.5)
Factors Associated with Lower Odds of Biologic Use
Primary care provider density 0.98 (0.94–1.01) 0.92 (0.86–0.98)
6.2 per 10,000
(sample mean)
36.9 (34.8–39.1)
7.2 per 10,000
(one unit increase)
35.8 (33.4–38.1)
Part D low-income subsidy Full Reference 50.6 (44.9–56.3)
None 0.36 (0.29–0.45) 0.30 (0.19–0.46) 27.2 (23.5–30.9)
Race White Reference 38.2 (35.9–40.5)
Black 0.55 (0.31–0.99) 0.31 (0.16–0.60) 19.8 (11.4–28.1)
Cancer No Reference 38.2 (35.9–40.5)
Yes 0.38 (0.26–0.56) 0.47 (0.31–0.72) 25.7 (19.4–31.9)
Dementia No Reference 37.7 (35.5–39.8)
Yes 0.41 (0.13–1.28) 0.26 (0.07–0.97) 17.2 (2.1–32.3)
Abbreviation: RxHCC, prescription drug hierarchical condition category risk score.
1Moderate to severe psoriasis is identiﬁed by receipt of either phototherapy, oral systemic, or biologic therapy.
2On the basis of a multivariable logistic regression model including the following covariates: age, sex, race, census region of residence, county-level per-
capita income, county-level poverty rate, county-level urban versus rural status, county-level low educational level, density of dermatologists and adult
primary care providers per number of residents in the patient’s county of residence, part D plan type, low-income subsidy status, number of non-psoriasis
medications, RxHCC score, and comorbid disease status including all components of the Charlson comorbidity index, autoimmune diseases for which
biologic therapies are indicated, cardiovascular risk factors, and aggregate of atherosclerotic outcomes.
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outcomes may also be affected by misclassiﬁcation (Quan
et al., 2008). The prevalence of psoriatic arthritis claims was
in accordance with population-based estimates of 6 to 17%
for psoriasis patients (Shbeeb et al., 2000; Gelfand et al.,
2005a; Ibrahim et al., 2009; Wilson et al., 2009; Ogdie et al.,
2013; Lofvendahl et al., 2014).
In our study, 16.4% of patients were not receiving treat-
ment for their psoriasis; this is lower than the approximately
40% of patients with psoriasis who were reported to not be
receiving treatment in two published surveys of National
Psoriasis Foundation members (Horn et al., 2007; Armstrong
et al., 2013). Similar to claims based psoriasis prevalence, we
suspect that the prevalence of untreated psoriasis patients in
our study is an underestimate because of our inability to
capture those patients, especially with mild disease, who are
not receiving care for their psoriasis. Phototherapy was
received by a mere 7% of patients. This observation is
consistent with the declining phototherapy usage rates
observed in the United States (Housman et al., 2002; Shaw
et al., 2014), which are suggested to result from a combination
of factors including poor reimbursement rates (especially for
Medicare recipients) (Lebwohl, 2013), greater out-of-pocket
costs to patients compared with biologics (Yentzer et al., 2009),
and greater time commitment required from the patient, despite
phototherapy being a ﬁrst-line, effective, and a well-tolerated
treatment for moderate-to-severe psoriasis (Menter et al., 2008).
Oral systemic medications, namely methotrexate, were found
to be the most common treatments for beneﬁciaries receiving
therapies used for moderate-to-severe psoriasis, followed by
biologics with approximately one-third of beneﬁciaries having
received a biologic in 2011. Among biologic therapies,
self-administered biologics were used by most patients,
perhaps reﬂecting patient preferences for subcutaneous self-
injectables over intravenous biologics, a ﬁnding suggested by
previous studies of patients with rheumatoid arthritis who are
candidates for similar biologics (Barton, 2009; Huynh et al.,
2014). The prevalence of ustekinumab claims in our study was
predictably low, perhaps owing to its more recent approval by
the Food and Drug Administration for treatment of moderate-
to-severe psoriasis in September 2009 compared with the other
biologics.
Examination of the factors associated with biologic use
among those patients receiving therapies used to treat
moderate-to-severe psoriasis revealed both expected and, to
our knowledge, previously unreported ﬁndings. Medicare
beneﬁciaries lacking LIS under the Part D plan had 70% lower
odds of receiving biologics compared with their counterparts
with LIS that allowed for minimal out-of-pocket drug costs for
self-injectable biologics (approximately $3 to $6 copayment
depending on income levels), independent of other patient
and plan characteristics. Moreover, patients without LIS may
face substantially greater costs for several of the Part D
covered biologics with 25 to 33% co-insurance within the
initial coverage limit and 50% of the drug costs in the Part D
coverage gap. We also found black beneﬁciaries to be
approximately 70% less likely to receive biologics compared
with white beneﬁciaries. LIS status (Zhang et al., 2013) and
black race (Schmajuk et al., 2011; Solomon et al., 2012; Chu
et al., 2013) have been similarly associated with biologic use
in studies of patients with rheumatoid arthritis. Together, these
ﬁndings suggest the presence of economic and racial factors
that may impact the treatment of moderate-to-severe psoriasis
and merit further study.
Expectedly, higher dermatology provider density and
residence in an urban county setting were each associated
with greater odds of receiving biologics. The presence of
comorbidities for which biologic treatment is indicated (i.e.,
ankylosing spondylitis, inﬂammatory bowel disease, and
psoriatic arthritis) was also associated with greater odds of
receiving biologics. Patients with a history of renal disease
were twice as likely to receive biologic therapy as patients
without renal disease, likely because of the relative contra-
indication to methotrexate use among those with renal
insufﬁciency. On the other hand, patients with a history of
cancer, a relative contraindication to biologics, and those
with dementia were less likely to receive biologics compared
with patients without cancer and dementia, respectively.
Finally, it is notable that the likelihood of receiving a biologic
did not differ between those who qualiﬁed for Medicare
based on their age versus those who qualiﬁed because of
disability.
Our study has several strengths, including the use of
Medicare claims data that are representative of the elderly
(65 years and older) population in the United States, 93% of
whom were enrolled in Medicare in 2011 (Centers for
Medicare and Medicaid Services, 2011), making our
ﬁndings generalizable to the majority of this population who
has fee-for-service Medicare with Part D drug coverage.
Medicare data have high-quality information on demo-
graphics, clinical encounters, and prescriptions for beneﬁci-
aries. In particular, race data have been shown to be valid for
whites and blacks (Zaslavsky et al., 2012). There are also
several limitations of our study to consider. Misclassiﬁcation
of psoriasis (Icen et al., 2008) and comorbidities (Quan et al.,
2008) as identiﬁed by administrative claims is possible. We
identiﬁed patients with psoriasis by the presence of at least
two claims for ICD-9-CM 696.1, which has been suggested to
have a positive predictive value of 70% (Icen et al., 2008).
This deﬁnition was preferred over that of at least one claim for
psoriasis by a dermatologist in order to balance our efforts to
minimize misclassiﬁcation and avoid selection of a more
severe population of psoriasis patients who would be more
likely to see a dermatologist. Furthermore, because our study
relies on medical claims to identify patients with psoriasis, our
results may underestimate the true prevalence of psoriasis
among the elderly. Our study also encompasses data from
2011 that may not be representative of the current state of
psoriasis treatment among the elderly, particularly for those
receiving ustekinumab, which was approved for psoriasis in
September 2009. As data on direct measures of psoriasis
severity were unavailable, we used treatment as a proxy to
deﬁne severity that may have resulted in misclassiﬁcation. We
also lacked information on other patient- and provider-level
factors such as individual income or education status,
or provider prescription patterns that may further affect
biologic use. Finally, our ﬁndings may not be generalizable
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to beneﬁciaries enrolled in Medicare managed care
(i.e., Medicare Advantage or Part C) plans and non-
Medicare patient populations.
Our study is, to our knowledge, the ﬁrst to examine the
epidemiology and treatment of psoriasis in the United States
Medicare population. We found the claims based prevalence
of psoriasis to be lower than population-based estimates.
Cardiometabolic disorders and depression were prevalent
among Medicare beneﬁciaries with psoriasis, conﬁrming
previous epidemiologic studies performed in generally
younger populations and possibly suggesting an even greater
burden of comorbid disease among the elderly psoriasis
population. Phototherapy was underutilized, consistent with
the decreasing use of phototherapy in the United States
(Housman et al., 2002; Shaw et al., 2014). Oral systemic
medications were used by more than half of the Medicare
beneﬁciaries receiving therapies indicated for moderate-to-
severe psoriasis, followed closely by biologic use at approxi-
mately 37%. Notably, our data identify potential ﬁnancial and
racial barriers to psoriasis patients receiving biologic thera-
pies. To improve psoriasis treatment, future studies should
evaluate whether similar barriers also exist for other popula-
tions, such as those with private insurance, Medicaid, or other
medical coverage programs. Collectively, our ﬁndings pro-
vide an important addition to the limited literature on psoriasis
and its treatments among the elderly and highlight areas for
future study.
MATERIALS AND METHODS
Data source, study population, design
We performed a retrospective claims analysis of the 2011 5%
Medicare Chronic Condition Warehouse ﬁles available from the
United States Centers for Medicare and Medicaid Services (CMS).
Medicare is a nationwide health insurance program administered by
the United States federal government for the elderly (65 years and
older) and the disabled. Medicare data are broadly representative
of the elderly population in the United States. We estimated the
annual cross-sectional prevalence of psoriasis claims among
beneﬁciaries with continuous fee-for-service Medicare Part A
(hospital insurance) and B (medical insurance) coverage and stand-
alone Part D (prescription drug) plan enrollment in 2011. In our
primary analyses, we also examined patient demographics,
socioeconomic status, Medicare plan characteristics, clinical
characteristics, and treatments for psoriasis among patients who
had at least two inpatient or outpatient claims for psoriasis, identiﬁed
by ICD-9-CM code 696.1. In secondary analyses, we identiﬁed
psoriasis by at least one inpatient or outpatient claim for psoriasis
by a dermatologist and present data in Supplementary Tables 1–4
online.
Claims based psoriasis prevalence
Claims based psoriasis prevalence was examined using eight
algorithms (Table 1): (i) at least one inpatient or outpatient claim
for ICD-9-CM 696.1 (psoriasis); (ii) at least one inpatient or two
outpatient claims for ICD-9-CM 696.1; (iii) at least two inpatient or
outpatient claims for ICD-9-CM 696.1; (iv) at least one inpatient
or outpatient claim for ICD-9-CM 696.1 by a dermatologist; (v) at
least one inpatient or outpatient claim for ICD-9-CM 696.1 or 696.0
(psoriatic arthritis); (vi) at least one inpatient or two outpatient claims
for ICD-9-CM 696.1 or 696.0; (vii) at least two inpatient or outpatient
claims for ICD-9-CM 696.1 or 696.0; and (viii) at least one inpatient
or outpatient claim for ICD-9-CM 696.1 or 696.0 by a dermatologist
or a rheumatologist. As most patients with psoriatic arthritis also have
psoriasis (Gladman et al., 2005; Love et al., 2007), our algorithms
explored the use of ICD-9-CM codes for both psoriasis (696.1) and
psoriatic arthritis (696.0). Provider specialty was determined using
the Medicare provider specialty supplemental ﬁle. Algorithm (ii) was
used for our main analyses. This algorithm was selected to minimize
psoriasis misclassiﬁcation, avoid limitation of the study population to
more severe cases presenting to dermatologists, and minimize
inclusion of those with concomitant psoriatic arthritis, as having
arthritis may have driven therapy decisions and affected treatment
patterns.
Psoriasis treatments
We examined the prevalence of topical therapies, phototherapy,
and oral systemic and biologic medications used to treat psoriasis
among all Medicare beneﬁciaries with psoriasis. The prevalence of
phototherapy, oral systemics, and biologics among patients identiﬁed
as having moderate-to-severe psoriasis was also determined. Topical
therapies included corticosteroids, calcineurin inhibitors, vitamin D
analogs, coal tar or anthralin, retinoids (i.e., tazarotene), and salicylic
acid. Phototherapy included both UVB and psoralen and UVA.
Oral systemic therapies included methotrexate, cyclosporine,
and acitretin. Biologic therapies included adalimumab, alefacept,
etanercept, inﬂiximab, and ustekinumab.
Psoriasis severity
In the absence of direct measures of psoriasis severity in claims data,
per convention, the receipt of phototherapy, oral systemic, or
biologic was used as a proxy to deﬁne moderate-to-severe psoriasis
(Gelfand et al., 2006a, b; Seminara et al., 2011; Wu et al., 2012).
Mild psoriasis was deﬁned by the absence of therapy or the receipt of
topical therapies only.
Variables
Patient and Medicare plan characteristics served as covariates in
regression analyses and were summarized descriptively. Patient
demographics and characteristics included age, sex, race, census
region of residence, reason for Medicare eligibility (aged or disabled),
and Part D LIS status. County-level socioeconomic characteristics
included per capita income, poverty rate, urban versus rural status,
and low educational level. The density of dermatologists and adult
primary care providers per number of residents in the patient’s county
of residence was used as a measure of availability of and/or access to
dermatologists and primary care providers, respectively. Clinical
variables included speciﬁc comorbid disease status including other
immune-mediated diseases for which biologic therapies are indi-
cated (i.e., ankylosing spondylitis, inﬂammatory bowel disease,
psoriatic arthritis, and rheumatoid arthritis), cardiovascular disease
risk factors, an aggregate of atherosclerotic outcomes (i.e., cerebro-
vascular disease, myocardial infarction, and peripheral vascular
disease), components of the Charlson comorbidity index (Quan et al.,
2005), and other measures of comorbidity including the total number
of non-psoriasis medications, and RxHCC risk score. Each comorbid
disease was deﬁned by at least two inpatient or outpatient claims for
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the disease of interest. The RxHCC score was originally created using
the RxHCC model to predict each Medicare beneﬁciary’s total drug
spending in the following year based on indicators for 197 medical
conditions identiﬁed from Medicare claims (Robst et al., 2007).
Although the RxHCC risk score was designed for Medicare
prescription drug plan payment purposes, it has been used to
adjust for potential selection biases in medical and drug use studies
among Medicare patients (Doshi et al., 2010; Donohue et al., 2012;
Li et al., 2012, 2014). Furthermore, the RxHCC model was adapted
from the hierarchical condition category risk adjustment model,
which has been shown to be a better predictor of mortality compared
with other comorbidity measures such as the Charlson and Elixhauser
comorbidity indices (Li et al., 2010). Unlike the ofﬁcial RxHCC risk
score that includes weights for age and sex, our score was based on
medical conditions only, allowing us to independently examine age
and sex effects in regression analyses. Medicare Part D plans cover
drugs that are approved for self-administration (i.e., topicals, orals,
and the self-administered biologics adalimumab and etanercept). Part
D plan characteristics include type of Part D beneﬁt (deﬁned
standard beneﬁt, actuarially equivalent standard, basic alternative,
and enhanced alternative). Except for the enhanced alternative
beneﬁt, all Part D beneﬁts provide basic beneﬁts, which include
deﬁned standard coverage or beneﬁts that are actuarially equivalent
to the standard coverage. LIS is generally provided to Part D
beneﬁciaries who are ﬁnancially disadvantaged and allows for
minimal out-of-pocket drug costs to those receiving the subsidy
compared with non-LIS beneﬁciaries.
Analysis
We used descriptive statistics to calculate the prevalence of psoriasis
claims and summarize demographic, socioeconomic, Medicare plan
and comorbid disease characteristics, and psoriasis therapies.
Multivariate logistic regressions adjusted for clustering at the
Medicare plan level were used to identify the factors associated with
biologic use. All variables except for psoriasis therapies were included
in the logistic regressions in order to determine which factors were
associated with biologic use; the aggregate atherosclerotic outcomes
variable was included in place of individual cerebrovascular disease,
myocardial infarction, and peripheral vascular disease variables.
Parsimonious models removing clinically or statistically non-
signiﬁcant variables were also evaluated and produced similar results
to the full regression models. Risk-adjusted rates were calculated from
the full multivariate logistic regression model. There were no missing
data; variables with designated “other” or “unknown” values were
included as such. Statistical signiﬁcance was determined by a two-
tailed P-valueo0.05. All analyses were performed using Stata (Version
13, StataCorp, College Station, TX).
Protection of human subjects
This study was approved by the University of Pennsylvania
Institutional Review Board and CMS (Data Use Agreement
25762). Per CMS Data Use Agreement, any data cells contain-
ing o11 beneﬁciaries were not shown. The study was con-
ducted in accordance with the Declaration of Helsinki and
reported in accordance with the Strengthening the Reporting of
Observational Studies in Epidemiology guidelines (von Elm et al.,
2007).
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